Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia — Stella

Recruiting

Back to Aggressive NK Cell Leukemia trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

Japan

Hiroshima University Hospital, Hiroshima, Hiroshima

Key details

Phase

First-in-human testing / Safety & dosing

Sponsor

Hiroshima University Hospital

Collaborators

Kyoto University Hospital, Hokkaido University Hospital

Enrollment target

~7 participants

Started

September 2023

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov